NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE…
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based…
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data…
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…
November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC,…
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA,…
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…
CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort…
Jerry Carter and Mackenzie Laughridge Join to Drive Growth and Expand Virtual Nursing SolutionsASHBURN, VA / ACCESSWIRE / November 12,…
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials,…